Pensacola, FL (April 12, 2018)-ActiGraph, a leading provider of medical-grade wearable activity and sleep monitoring solutions, is collaborating with Bayer in an ongoing pilot study evaluating usability and patient perceptions of a digital tool suite consisting of Clinical Ink’s SureSource Engage mobile application, an ActiGraph activity monitor, and a Bluetooth-enabled weight scale. The study aims to examine the feasibility of implementing remote-monitoring technology in Bayer’s future clinical trials as a means to improve patient engagement, enhance patient support, and expose trends in patient behaviors that could ultimately help get medicines to the patients who need them faster and more efficiently. The study, conducted by Health Innovation Technology Lab (HITLAB), is divided into two month-long phases, during which participants use the SureSource Engage app, wear an ActiGraph GT9X Link activity monitor for 24 hours/day, and measure their weight with a Bluetooth-enabled scale. At the completion of phase one, the study team collected comprehensive feedback from the participants to understand how they perceived and interacted with the technology and to identify specific areas for improvement. Improvements for phase two of the study included the use of ActiGraph’s CentrePoint Data Hub, a home-based communication device that helps minimize the burden on participants by passively uploading activity monitor data to a centralized cloud platform via cellular network. “We are excited to work together with ActiGraph in an effort to support the patient journey. Our hopes are to create a better experience for all involved with our clinical trials while enhancing our data collection efforts. By listening to the patient’s voice, we have the ability to improve our study designs of the future and ultimately help patients get the medicines they need,” explained Michelle Shogren, Pharmaceuticals R&D Portfolio and Operations at Bayer. About ActiGraph ActiGraph is a leading provider of medical-grade physical activity and sleep monitoring solutions for the global scientific community. ActiGraph’s wearable actigraphy monitors and robust analytics platform have been widely used in academic and population health research for nearly two decades. In recent years, the company’s monitoring solutions have been steadily adopted by biopharma and life sciences organizations seeking to capture real-world objective outcomes related to physical activity, mobility, and sleep behavior for patients enrolled in clinical trials. To learn more about ActiGraph’s wearable actigraphy monitoring solutions, CentrePoint technology ecosystem, and end-to-end clinical trial services, please visit actigraphcorp.com/clinicaltrials or contact us at pharma@actigraphcorp.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.